Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02767505
Other study ID # 478-15, version 5 2020-03-23
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 2015
Est. completion date December 2031

Study information

Verified date February 2024
Source Göteborg University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is nationwide registry-based randomised clinical multicenter trial in which patients will be randomised to gastric bypass (RYGB) or sleeve gastrectomy (SG). The co-primary endpoint are weight control over 5 years and the amount of severe adverse events. Additionally the investigators have predefined a number of secondary endpoints, and the trial has a sufficient number of patients to allow comparisons across subgroups.


Description:

Follow-up of the patients will use the routines respectively for regular follow-up on the Scandinavian Obesity Surgery Registry (SOReg) after 6v, 1 year, 2 years, and after 5 years. In order to evaluate if SG has advantages compared to the previous standard, the investigators want to examine whether SG operations are equivalent (non-inferiority) for weight loss and weight stability five years after surgery in comparison to RYGB, and if SG is associated with fewer long-term complications (superiority). The primary outcome measure emanates from assessment of long term weight management and the frequency of serious complications. The unforeseen global Covid-19 pandemic resulted in that almost all elective benign surgery in Scandinavia was cancelled from March 2020. Thus, the pandemic had severe consequences on the recruitment to the BEST trial during 2020-2021. During autumn of 2021 the BEST steering committee decided to perform an additional analysis of the power for primary endpoints. Additional information (Courcoulas et al, JAMA Surg 2020 March; Howard et al, JAMA Surg 2021 Dec) revealed that the risk of any of the predefined substantial adverse events after bariatric surgery is higher than previously anticipated in the revised power calculation, i.e. >25% instead of 13%. These figures were confirmed in an analysis of real-world data from the bariatric national quality register SOReg in Sweden which registered all patients undergoing sleeve or bypass in Sweden since 2007. An independent statistician performed the analysis based on information above, but also on 2-year data in BEST. In conclusion, it was stated: Two post hoc power analyses were conducted based on the data from February 2022: 1. Weight reduction. In the protocol the following is stated "This sample size will also have >95% power to evaluate non-inferiority of 5% weight loss difference over 5 years between the two groups, assuming 15 kg standard deviation in weight loss over follow-up with two-sided 2.5% significance level.". The post hoc power calculation is based on the two-year follow up data where an average weight loss for all patients (both groups, N=1031) of 29.3 kg was attained with a Sd=21.6. Given a loss to follow up of 20% from 2 year follow up to the 5-year follow up the sample size is assumed to be (1031*0.80)/2=413 patients per group. With a non-inferiority level of 5 kg weight loss the power is found to be 90% if n=393 per group, and 95% if n=486 per group (https://www.sealedenvelope.com/power/continuous-noninferior/). 2. Substantial adverse events. This post hoc power calculation is for a superiority test where the rate is assumed to be 25% for the gastric bypass at 5 years and sleeve would have a 35% lower level, i e 25%*0.65=16.25%. Given a sample of n=413 per group the post hoc power will then be 87.5%. Taking information above into account and in the interest of not prolonging inclusion period unnecessarily the trial steering committee took a decision to stop inclusion in BEST during spring 2022 (final date 31st of March). At termination of inclusion the number of participants that had been included and operated in BEST were 1752. The trial Data Safety and Monitoring Committee reviewed and supported the decision before termination of recruitment to the BEST trial.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 1752
Est. completion date December 2031
Est. primary completion date December 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - BMI 35-50 kg/m2 - Ability to understand and decide on the merits of the study participation - Accepted for bariatric surgery - Must understand the information, and be able to make a decisions about participation in the study Exclusion Criteria: - Previous bariatric surgery, anti reflux surgery or other gastric surgery - Moderate to severe reflux disease, Barretts oesophagus or known hiatus hernia >4 cm - Unstable mental illness or other known contraindication to bariatric surgery. - Planned significant surgery at the same time - Inflammatory bowel disease - ongoing drug or substance abuse - not appropriate to randomise the patient, according to surgeon

Study Design


Related Conditions & MeSH terms


Intervention

Other:
gastric bypass
Type of surgery: gastric bypass
Sleeve gastrectomy
Typ of surgery: sleeve gastrectomy

Locations

Country Name City State
Norway Sentralsykehuset Vestfold Tønsberg
Sweden Falu Hospital Falun
Sweden Gävle Hospital Gävle
Sweden Östra Hospital Göteborg
Sweden Kalmar County Hospital Kalmar
Sweden Lindesbergs Hospital Lindesberg
Sweden Linköping University Linköping
Sweden Ljungby Hospital Ljungby
Sweden Lycksele Hospital Lycksele
Sweden Mora Hospital Mora
Sweden Vrinnevi Hospital, Norrköping Norrköping
Sweden Örebro University Hospital Örebro
Sweden GB Obesitas Skåne
Sweden Skaraborgs Hospital Skövde
Sweden Södertälje Hospital Södertälje
Sweden Capio S:t Görans Hospital Stockholm
Sweden Danderyds Hospital Stockholm
Sweden Ersta Hospital Stockholm
Sweden Stockholm South General Hospital Stockholm
Sweden Torsby Hospital Torsby
Sweden Uppsala University Hospital Uppsala

Sponsors (22)

Lead Sponsor Collaborator
Göteborg University Capio S:t Görans Hospital, Danderyd Hospital, Ersta Hospital, Sweden, Falu Hospital, Gävle Hospital, GB Obesitas Skane, Gjövik Hospital, Norway, Kalmar County Hospital, Lindesbergs Hospital, Ljungby Hospital, Lycksele Hospital, Mora Hospital, Östra Hospital, Region Örebro County, Skaraborg Hospital, Sodertalje Hospital, Stockholm South General Hospital, Sykehuset i Vestfold HF, Torsby Hospital, Uppsala University Hospital, Vrinnevi Hospital, Norrköping

Countries where clinical trial is conducted

Norway,  Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Weight loss Non-inferiority for SG is defined as < 5% weight difference 5 years
Primary Serious adverse events Superiority for SG is having 35% less serious (substantial) adverse events compared to RYGB 5 years
Secondary Adverse events General description of patterns of all adverse events 1, 2, 5 and 10 years
Secondary Weight loss Between baseline and 1 and 2 years Baseline, 1, 2, 5 and 10 years
Secondary Number of patients with arterial cardiovascular events Composite of myocardial infarction+ stroke+ other occlusive arterial condition Baseline, 1, 2, 5 and 10 years
Secondary Number of patients with venous event Composite of Deep vein thrombosis+ Pulmonary emboli+ other venous event Baseline, 1, 2, 5 and 10 years
Secondary Number of patients with diabetes requiring drug treatment Development of diabetes measured as numbers of patients having a diabetes diagnosis and oral medication and injection therapy Baseline, 1, 2, 5 and 10 years
Secondary Number of patients with a psychiatric morbidity Number of patients with a psychiatric morbidity Baseline, 1, 2, 5 and 10 years
Secondary Number of patients with hypertension treatment Number of patients with hypertension treatment (any type of Medical treatment) Baseline, 1, 2, 5 and 10 years
Secondary Number of patients diagnosed with a malignancy Number of patients diagnosed with a malignancy Baseline, 1, 2, 5 and 10 years
Secondary Number of patients with dyslipidemia treatment Number of patients with diagnosis of dyslipidemia and on oral lipid lowering treatment Baseline, 1, 2, 5 and 10 years
Secondary Weight in men and women Analyses of the primary outcome weight in men and women Baseline, 1, 2, 5 and 10 years
Secondary serious adverse events in men and women Analyses of the primary outcome serious adverse events in men and women Baseline, 1, 2, 5 and 10 years
Secondary Weight in patients with BMI >43 vs <43 kg/m2. Analyses of the primary outcome weight in patients with BMI >43 vs <43 kg/m2. Baseline, 1, 2, 5 and 10 years
Secondary Serious adverse events in patients with BMI >43 vs <43 kg/m2 Analyses of the primary outcome serious adverse events in patients with BMI >43 vs <43 kg/m2. Baseline, 1, 2, 5 and 10 years
Secondary Weight in patients aged 18-25 y, 25-50 y, or >50 y Analyses of the primary outcome weight in patients aged 18-25 y, 25-50 y, or >50 y Baseline, 1, 2, 5 and 10 years
Secondary Serious adverse events in patients aged 18-25 y, 25-50 y, or >50 y Analyses of the primary outcome serious adverse events in patients aged 18-25 y, 25-50 y, or >50 y Baseline, 1, 2, 5 and 10 years
Secondary Mineral nutritional status Serum concentrations of iron depots, zinc, magnesium, selenium and copper Baseline, 1, 2, 5 and 10 years
Secondary Vitamin nutritional status Serum concentrations of vitamins (Vitamin B12, Vitamin D, Vitamin A, thiamin) Baseline, 1, 2, 5 and 10 years
Secondary Serum concentrations of albumin Serum concentrations of Albumin Baseline, 1, 2, 5 and 10 years
Secondary Changes in quality of Life assessed with EQ-5D Assessed with EQ-5D Baseline, 1, 2, 5 and 10 years
Secondary Changes in quality of Life assessed with Obesity Problems (OP) Assessed with Obesity Problems (OP) Baseline, 1, 2, 5 and 10 years
Secondary Changes in quality of Life assessed with Short Form-36 Assessed with SF-36 Baseline, 1, 2, 5 and 10 years
Secondary Alcohol consumption Assessed by AUDIT 1, 2, 5 and 10 years
Secondary Gastro-esophageal reflux disease Gastro-esophageal reflux disease is defined as present/ not present in at least one of following modalities: Questionnaire DeMeester score, 24h pH manometry and/or gastroscopy 1, 2, 5 and 10 years
Secondary Fracture incidence From clinical data and national registry 2, 5 and 10 years
Secondary Bone density and body composition Dual energy X-ray Absorptiometry (DEXA) in at least a subgroup of 500+500 10 years
Secondary Mortality and cause of death National Cause of Death registry 5, 10, 20 and 30 years
Secondary Health care consumption, In hospital registry Data from In hospital registry (Days in hospital) 5, 10, 20 and 30 years
Secondary Health care consumption, Data from Outpatient registry ( number of visits) 5, 10, 20 and 30 years
Secondary Health care consumption National drug registry (type of drug) 5, 10, 20 and 30 years
Secondary Development of co-morbidities from national registry data National stroke registry, National Cardiac registry, National Diabetes Registry, Cancer registry 5, 10, 20, 30 years
Secondary Formal cost effective analysis Cost per quality-adjusted life-year and life-year) 5, 10 and 20 years
Secondary Dietary intake Questionnaire regarding food intake (E14x) 1 and 10 years
Secondary Eating patterns Three Factor Eating Questionnaire (TFEQ) 1 and 10 years
Secondary Gastro-intestinal side effects Questionnaire: Gastro-intestinal Symptom Rating Score (GSRS) 1 and 10 years
Secondary Dumping symptoms Questionnaire: Dumping Symptom Rating Score (DSRS) 1 and 10 years
Secondary Adverse events Clinical data combined with national registry data 30 days postop, 1, 2, 5 and 10 years
Secondary Peri-operative outcome, Complications Complications; Surgical (minor/major) and medical Up to 30 days postop
Secondary Peri-operative outcome, surgical time surgical time (min) Up to 30 days postop
Secondary Peri-operative outcome, sick leave sick leave (days) Up to 30 days postop
Secondary Peri-operative outcome, length of stay length of stay (days) Up to 30 days postop
See also
  Status Clinical Trial Phase
Completed NCT03690752 - Adherence to Walking on an Alter G Anti-Gravity Treadmill N/A
Recruiting NCT05786092 - Impact of Telemonitoring on Metabolic Variables in Severe Obesity N/A
Active, not recruiting NCT03249441 - Compassion-Focused Therapy for People With Severe Obesity. N/A
Terminated NCT04626232 - Comparison of the Sleeve Gastrectomy Technique With a Nissen Fundoplication Added to the Conventional Sleeve Gastrectomy Technique in Morbidly Obese Patients N/A
Completed NCT02952963 - Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass Phase 4
Active, not recruiting NCT02374632 - Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass Phase 4
Active, not recruiting NCT04165694 - Single Anastomosis Duodenal Ileal Bypass (SADI) for Sleeve Revision N/A
Not yet recruiting NCT06162715 - GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Feasibility Trial Phase 2
Completed NCT05409612 - Trial Assessing the Immunogenicity and Safety of Two Influenza Vaccine Strategies Among Severe Obese Adult Patients Phase 3
Completed NCT03638895 - Energy Expenditure From ECAL Indirect Calorimeter in a Multicomponent Weight Management Service N/A
Not yet recruiting NCT05493592 - Pigeon Peas (Cajanus Cajan) : a Natural Anti-inflammatory Facilitating Weight Loss in Obese Patients Returning to Sport? N/A
Completed NCT02823561 - Garcinia Mangostana Extracts in the Management of Weight Loss Phase 4
Completed NCT02340247 - Effects of Bile Acids on GLP-1 Secretion After Roux-en-Y Gastric Bypass Phase 4
Recruiting NCT02076880 - SLEEVEDIAB To Explore the Early and Late Metabolic Effects of Sleeve Gastrectomy in Obese Patients N/A
Completed NCT04042493 - Connect for Health Pediatric Weight Management Program N/A
Completed NCT04129801 - Muscle Strength in Severe Obese Patients in the Postoperative of Bariatric Surgery
Completed NCT05341414 - Trajectories of Resilience and Bariatric Surgery Outcomes
Recruiting NCT02710786 - Comorbidity After Gastric Bypass
Recruiting NCT02409160 - Sleep and Immune Response in Severe Obese Patients Undergoing Bariatric Surgery. N/A
Completed NCT00623792 - Study on Impact of Lifestyle Change and Weight Loss Before Bariatric Surgery N/A